LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$18.97M, compared with -$5.22M a year earlier. Trailing-twelve-month EBITDA was -$39.05M.
Context
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +60.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$18.97M-66.6% QoQ
- Last fiscal yearDec 2025
- -$24.88M+60.5% YoY
- LTMMar 2026
- -$39.05M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -263.7% | +100.0% | +363.7 pp |
| 1 year | +60.5% | +100.0% | +39.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (24.88M) USD
- Year-over-year change
- +60.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (24.88M) | +60.5% |
| FY2024 | 2024-12-31 | (63.01M) | -4260.6% |
| FY2023 | 2023-12-31 | (1.45M) | +88.1% |
| FY2022 | 2022-12-31 | (12.19M) | — |
EBITDA vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's LTM Mar 2026 EBITDA of -$39.05M is the 2nd highest of the 10 companies compared; the peer median is -$198.91M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $140.29M | +5.0% | — | 11.7% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$39.05M | — | — | — |
| LTM Mar 2026 | -$55.86M | -33.8% | — | — | |
| LTM Mar 2026 | -$71.29M | -16.9% | — | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$118.15M | -28.2% | — | 590.7% |
| LTM Mar 2026 | -$198.91M | -147.8% | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$217.64M | +15.4% | — | — |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | -$323.53M | -99.1% | — | — |
| LTM Jun 2026 | -$394.35M | -3608.6% | — | — | |
| LTM Jun 2026 | -$498.21M | -6.5% | — | 13823.7% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | -$198.91M | -28.2% | — | 590.7% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 1.35M | 7.85M | 51.17M | 16.74M |
| Selling, General & Admin | 1.46M | 3.53M | 13.66M | 13.66M |
| Operating Expenses | 2.81M | 11.38M | 64.83M | 30.4M |
| Depreciation & Amortization | 2K | 4K | 91K | 321K |
| EBITDA | (12.19M) | (1.45M) | (63.01M) | (24.88M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (2.81M) | (11.38M) | (64.83M) | (30.4M) |
| Operating Margin | — | — | — | — |
| Interest Income | 73K | 811K | 1.72M | 3.92M |
| Interest Expense | 2.15M | 4.83M | 0 | 0 |
| Other Income / Expenses | (11.54M) | 5.1M | 1.73M | 5.2M |
| Income Before Tax | (14.35M) | (6.27M) | (63.1M) | (25.2M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1K | 1K | 1K | 1K |
| Net Income | (14.35M) | (6.28M) | (63.1M) | (25.21M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (4.05) | (1.77) | (17.83) | (1.00) |
| EPS (Diluted) | (4.05) | (1.77) | (17.83) | (1.00) |
| Weighted Avg Shares | 3.54M | 3.54M | 3.54M | 25.3M |
| Weighted Avg Shares (Diluted) | 3.54M | 3.54M | 3.54M | 25.3M |
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.